What Is the Single Highest-ROI Move This Quarter in Healthtech / Digital Health?

The highest-ROI move for most healthtech companies this quarter is not a new feature — it's removing the biggest friction point in your activation-to-reimbursement path. In practice, that usually means one of three things: shortening time-to-first-clinical-value, closing a payer or provider contract that unblocks revenue, or fixing the onboarding step where clinicians or patients drop off. The way to know which one is to score your candidate initiatives with RICE (Reach, Impact, Confidence, Effort) instead of debating them by conviction.

This article walks through that scoring for a digital health company and shows where a tool like Percision helps — and where a spreadsheet or a fractional consultant is honestly enough.

Why "highest-ROI move" is a scoring problem, not a debate

Healthtech roadmaps get crowded fast because you serve at least three masters: patients (or members), the clinicians who prescribe or deliver care, and the payer/employer/provider who signs the check. Every stakeholder generates "obvious" priorities — a slicker patient app, EHR integration, HIPAA/SOC 2 completion, a new payer pilot, better clinical outcomes reporting.

The trap is ranking these by whoever argues loudest in the room. RICE forces a common denominator so a clinical outcomes dashboard and a Salesforce integration can be compared on the same axis. It's simple, transparent, and — critically — auditable when your board or investors ask why this and not that.

Running RICE on a healthtech roadmap: a concrete walkthrough

RICE scores each initiative on four factors and combines them into one number:

RICE Score = (Reach × Impact × Confidence) ÷ Effort

Here's how each factor translates in a digital health context. Score a handful of candidate initiatives — say, five to eight — and be disciplined about the questions.

Reach — How many people does this touch in the quarter? Use a real unit, not a vibe. For a chronic-care app: number of enrolled members who hit this flow per quarter. For a B2B2C deal: covered lives unlocked. Watch the healthtech distortion — a payer contract may have low user reach but massive revenue reach, so decide upfront whether you're scoring for adoption or for dollars, and keep it consistent.

Impact — How much does this move the metric that matters? Pick one north-star per initiative: activation rate, 90-day retention, clinical outcome (e.g., A1c reduction), or contracted ARR. Score on a simple scale (3 = massive, 2 = high, 1 = medium, 0.5 = low). Be honest: a UI refresh is usually a 0.5–1; an integration that removes a clinician's manual charting step can be a 2–3 because it changes prescribing behavior.

Confidence — How sure are you, backed by evidence? This is where healthtech teams over-rate themselves. Anchor confidence to data you actually have: usage analytics, a completed pilot, payer verbal commitment. 100% = strong evidence, 80% = some data, 50% = educated guess. A "payer will renew" assumption with no signed LOI is not 100%.

Effort — Person-months across product, engineering, clinical, and compliance. Healthtech's hidden cost is regulatory and clinical review — a feature touching PHI or clinical decision support carries validation and security effort a consumer app never does. Include it, or your scores will lie.

What "good" looks like: the exercise surfaces one or two initiatives with scores that dwarf the rest — often something with modest Reach but high Impact and Confidence and low Effort, like removing a single onboarding step. If everything scores the same, your Impact or Confidence estimates are too soft and you need to sharpen them, not the tool.

From score to execution plan

A ranked list is not a plan. Convert the winning initiative into: an owner, a single measurable target for the quarter (e.g., "lift 30-day activation from X to Y"), the two or three leading indicators you'll watch weekly, and an explicit list of what you're deprioritizing to fund it. Resource allocation only creates ROI when something loses budget so the winner gets a real team.

The most common healthtech failure here is starting three "top priorities" in parallel. RICE exists to force sequencing.

Where Percision fits — and where it doesn't

Full disclosure: I write for Percision, so treat this as one strong option, not the only path.

Percision is a strategic intelligence platform that runs your business context through structured reasoning — including resource-allocation and RICE-style prioritization — and produces board-ready output in roughly 7–15 minutes. For a healthtech leadership team, it's useful when you want to (a) pressure-test your Impact and Confidence scores against a structured analysis rather than internal optimism, (b) turn the ranking into a board-ready deck and an executive dashboard with KPI tracking, and (c) tie the prioritization to financial intelligence (DCF, ratios, warning signs) so the "highest-ROI move" claim is backed by numbers. It's a co-pilot: your leadership team keeps control of the final call.

When you don't need it: if you have five initiatives and a strong internal data culture, a shared spreadsheet and a 90-minute leadership session will get you there this week — that's genuinely enough. And if your real blocker is regulatory strategy, payer contracting nuance, or clinical validation design, a specialist human consultant is the better spend; those require domain judgment and relationships, not faster analysis. Use Percision to accelerate the structured work, not to replace domain expertise.

Broadly, research on generative AI in knowledge work — including a 2023 BCG field experiment with Harvard/Wharton/MIT researchers — found meaningful productivity and quality gains on structured tasks and negative effects when the tool was used outside its capability boundary. RICE scoring is squarely inside that boundary; payer negotiation is not.

FAQ

Q: Should we use user reach or revenue reach for a B2B2C healthtech RICE model? Pick one and hold it constant across all initiatives, then run the other as a second column if revenue and adoption diverge sharply. Mixing them within one score is the most common way to get a misleading ranking.

Q: How do we account for compliance and clinical review in Effort? Add them as explicit person-months alongside product and engineering. Any initiative touching PHI or clinical decision support should carry a validation and security line — omitting it systematically over-rates regulated features.

Q: How often should we re-run RICE? Once per quarter as a planning ritual, plus any time a major assumption breaks — a payer LOI lands, a pilot reads out, or a competitor ships. The scores are a snapshot, not a permanent truth.